Importantly, activated AKT promotes higher levels of FasL decoy receptor-3 (DcR3), which competitively binds to FasL, protecting IPF fibroblasts from FasL-mediated apoptosis [128]. The gene discussed is FASLG; the disease is idiopathic pulmonary fibrosis.